Identifying gaps in the implementation of naloxone programs for laypersons in the United States

Int J Drug Policy. 2018 Feb:52:52-55. doi: 10.1016/j.drugpo.2017.11.017. Epub 2017 Dec 9.

Authors

Barrot H Lambdin¹, Jon Zibbell², Eliza Wheeler³, Alex H Kral²

Affiliations

¹ RTI-International, San Francisco, CA, United States; University of California San Francisco, San Francisco, CA, United States; University of Washington, Seattle, WA, United States. Electronic address: blambdin@rti.org.
² RTI-International, San Francisco, CA, United States.
³ Harm Reduction Coalition, Oakland, CA, United States.

PMID: 29232604
DOI: 10.1016/j.drugpo.2017.11.017

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Cross-Sectional Studies
Drug Overdose / drug therapy*
Drug Overdose / mortality
Humans
Naloxone / administration & dosage*
Narcotic Antagonists / administration & dosage*
Opioid-Related Disorders / complications
Opioid-Related Disorders / drug therapy*
Opioid-Related Disorders / mortality
Program Development
Program Evaluation
United States

Substances

Narcotic Antagonists
Naloxone

Grants and funding

R34 DA039101/DA/NIDA NIH HHS/United States